



Ami Organics Limited

CIN No. : L24100GJ2007PLC051093

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

May 21, 2022

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

Scrip Code: 543349

NSE Symbol : AMIORG

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release dated May 21, 2022 regarding appointment of Chief Financial Officer of the Company.

This Press Release will be available on the website of the Company
www.amiorganics.com.

Kindly take the same on record.

Yours faithfully,
For, AMI ORGANICS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: Press Release





AMI ORGANICS LIMITED

Ami Organics Appoints Bhavin Shah as Chief Financial Officer

Incumbent CFO Abhishek Patel moves on to lead his family business

Surat, May 21, 2022: Ami Organics Limited (AMI) (BSE: 543349), NSE: AMIORG) today announced the appointment of Bhavin N. Shah as Chief Financial Officer of Company, effective June 01, 2022. Bhavin will take charge from serving CFO Abhishek Patel who will move on to take over his family business after a tenure of 4 years at AMI Organics. Bhavin N. Shah joined AMI Organics in March 2022 as Deputy Chief Financial Officer.

Bhavin, a qualified Chartered Accountant, brings more than 18 years of expertise in consulting, corporate accounts, and finance. Prior to joining AMI Organics, Bhavin was the Deputy General Manager in Sun Pharma Advanced Research Co. Ltd. (SPARC) where he was responsible for leading Accounts, Finance, Taxation, Banking Relations, and Fundraising. He has also led the finance team at Unimark Remedies and worked as a consultant with Deloitte Haskins & Sells.

Commenting on the development, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: *“For the last four years, Abhishek has been an integral part of AMI Organics and was responsible for effectively leading the finance function with his acumen and expertise. On behalf of the board, I thank him for his invaluable contribution to the organisation and wish him all the success in his next assignment.*

I would also like to congratulate and welcome Bhavin as he steps up in the role of Chief Financial Officer. Bhavin who recently came on board as a Deputy Chief Financial Officer, brings rich experience across various finance functions. I am sure he will add value to the organisation and help spearhead growth in the coming years.”

Commenting on the development, Mr. Abhishek Patel, said: *“I would like to express my gratitude to Mr. Naresh Patel for the trust he has shown in my capabilities and in allowing me to independently lead the finance function for AMI Organics. It has been an honour to work under his leadership and he has been a source of tremendous learning and motivation.”*

Commenting on his appointment, Mr. Bhavin Shah, said: *“I am extremely humbled to step up in the role of the CFO and lead the function under the guidance of Mr. Naresh Patel. He and Mr. Abhishek Patel have built a strong team at AMI and I am excited at the opportunity to add value as we remain steadfast in our mission to grow the organisation from strength to strength.”*

ABOUT AMI ORGANICS LIMITED:

Headquartered in Surat, Ami Organics is an R&D-driven manufacturer of specialty chemicals with varied end usage. The Company is focused on the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated markets and

PRESS RELEASE

For Immediate dissemination

**AMI ORGANICS LIMITED**

generic active pharmaceutical ingredients (“APIs”) and New Chemical Entities (“NCE”) and key starting materials for agrochemical and fine chemicals. AMI has developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at AMI Organics Ekta Srivastava, Company Secretary & Compliance Officer cs@amiorganics.com Ernst & Young LLP Mr. Rahul Thakur Rahul.Thakur@in.ey.com	Registered Office Plot no. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01017 NSE Code: AMIORG BSE CODE: 543349 Website: www.amiorganics.com
---	--